Role of the highly conserved Asp-Arg-Tyr motif in signal transduction of the CB2 cannabinoid receptor  by Rhee, Man-Hee et al.
Role of the highly conserved Asp-Arg-Tyr motif in signal transduction of
the CB2 cannabinoid receptor
Man-Hee Rhee, Igal Nevo, Rivka Levy, Zvi Vogel*
Department of Neurobiology, The Weizmann Institute of Science, Rehovot 76100, Israel
Received 7 December 1999; received in revised form 29 December 1999
Edited by Shmuel Shaltiel
Abstract The DRY motif, at the junction of transmembrane
helix 3 and intracellular loop 2 of G protein-coupled receptors, is
highly conserved. Mutations were introduced into the CB2
cannabinoid receptor to study the role of this motif in CB2
signaling. D mutations (DRY130^132AAA and D130A) mark-
edly reduced binding of cannabinoid agonists, while no significant
reduction was observed with R131A or Y132A. Mutating R
(R131A) only partially reduced, and mutating Y (Y132A) more
efficiently reduced the cannabinoid-induced inhibition of adenylyl
cyclase. Thus, in CB2, D130 is involved in agonist binding,
whereas Y seems to have a role in receptor downstream signaling.
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1. Introduction
Two subtypes of cannabinoid receptors, CB1 and CB2, have
been cloned to date [1,2]. Both CB1 and CB2 are members of
the seven transmembrane (TM) domain G protein-coupled
receptor (GPCR) superfamily. While CB1 is mainly present
in the central nervous system, the CB2 receptor has been
found to be expressed in immune cells (such as splenic macro-
phages, monocytes, B-cells and natural killer cells), as well as
in tonsil and bone marrow, but not in brain [2,3]. Moreover,
CB2-like cannabinoid receptors have recently been found on
peripheral nerve terminals [4,5]. Both CB1 and CB2 act via
Gi=o to inhibit adenylyl cyclase (AC) [6^8]. Relatively little is
known about the structure of the CB2 receptor and the mo-
lecular interactions involved in its ligand binding and signal
transduction.
The DRY motif at the junction of TM3 and the second
intracellular loop (ICL2) is highly conserved in most GPCRs
([9^12]; see Fig. 1) and is a candidate site for the interaction
of the receptor with the associated G protein [12,13]. The D
residue (residue 3.49 in the nomenclature of Ballesteros and
Weinstein [14]) is found in 94% of the rhodopsin-like GPCRs
[9]. A few receptors (e.g. rhodopsin, thyroid stimulating hor-
mone receptor, follicle stimulating hormone receptor) were
reported to have E instead of D at this site. Thus, this motif
has been de¢ned as the E/DRY motif, see [15]. Mutagenesis of
this site in various GPCRs (e.g. rhodopsin, GnRH, K1B-adren-
ergic and m1-muscarinic receptors) revealed that the D3.49
residue has a role in receptor expression [16,17], internaliza-
tion [16,18] and constitutive receptor activation [15,19,20].
However, di¡erent e¡ects were observed with di¡erent recep-
tors. For example, mutations at D3.49 of the K1B-adrenergic
receptor induced constitutive activation of inositol phosphate
production [19,20], but did not seem to directly a¡ect G pro-
tein signaling of the m1-muscarinic receptor [17]. The R3.50
(in the nomenclature of Ballesteros and Weinstein) is com-
pletely conserved in all GPCRs and appears to a¡ect the
receptor interaction with the coupled G proteins [9,11,21].
The Y3.51 of this E/DRY motif is found in 79% of the rho-
dopsin-like GPCRs [9] and is claimed to be involved in m1-
muscarinic receptor expression [17] and in the internalization
of the bradykinin B2 receptor [22,23].
In this study, we investigated the role of the DRY motif in
ligand binding and signal transduction of the CB2 cannabi-
noid receptor. We found that D130 is essential for the ca-
pacity of the CB2 receptor to bind cannabinoid agonists,
whereas Y132 has a role in the receptor downstream signaling.
2. Materials and methods
2.1. Materials
[2-3H]Adenine (18.0 Ci/mmol) was purchased from American Ra-
diolabeled Chemicals (St. Louis, MO, USA). The phosphodiesterase
inhibitors, 1-methyl-3-isobutylxanthine (IBMX) and RO-20-1724,
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Fig. 1. Location of the DRY motif in various GPCRs. (A) General
structure of the CB2 receptor. (B) Amino acid sequences in the E/
DRY area of several GPCRs, as obtained from [32,42,43].
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were from Calbiochem (La Jolla, CA, USA). Forskolin (FS), cAMP
and fatty acid-free bovine serum albumin (FAF^BSA) were from
Sigma (St. Louis, MO, USA). The cannabinoid agonists, HU-210,
WIN55,212-2 and [3H]HU-243 were kindly provided by Dr. R. Me-
choulam (Jerusalem, Israel). Tissue culture reagents were from Life
Technologies (Gaithersburg, MD, USA).
2.2. Plasmids
Rabbit AC type V (AC-V) and L-gal cDNAs in the pXMD1 vector
[24] were described previously [7,25]. The human CB2 cDNA in
pCDM8 [2] was kindly provided by Dr. S. Munro (Cambridge, UK).
2.3. Construction of hemagglutinin (HA)-tagged human CB2 in
pcDNA3
The following oligonucleotide primers (P1 and P2) were synthesized
and used to amplify (by PCR) an 1100 bp fragment containing the
entire human CB2 coding sequence (using the human CB2 cDNA in
pCDM8 as a template): P1, 5P-GCGGATCCGAGGAATGCTGG-
GTG-3P sense primer; P2, 5P-GCGCGGCCGCTCAGCAATCAGA-
GAG-3P antisense primer. P1 is homologous to the cDNA sequence at
the CB2 coding start site and was engineered to contain a unique
BamHI site (underlined) for in-frame subcloning into a BglII site at
the carboxy end of the HA sequence in HA-pcDNA3 [26]. The P2
sequence was designed to introduce a unique NotI site (underlined) for
ligation into the multiple cloning site of pcDNA3. The 1100 bp PCR
product (following 25 cycles of 1 min denaturation at 92‡C, 1 min
annealing at 45‡C and 1 min extension at 72‡C) was digested with
BamHI and NotI and cloned into the BglII and NotI sites of HA-
pcDNA3. The DNA sequence was con¢rmed by sequencing at the
Weizmann Institute’s DNA Sequencing Unit.
2.4. Preparation of point mutations in HA-CB2
Mutations were introduced using the PCR-overlap extension meth-
od as previously described [27]. In brief, two general primers were
designed for PCR that cover the region in HA-CB2 where the muta-
tions were planned. The 5P general primer 5P-TAATACGACTCAC-
TATAGGG-3P (complementing part of the T7 sequence of pcDNA3)
and the 3P general primer 5P-TTGACCTGGTCACTGAGCGTAGT-
3P (complementing a coding sequence in CB2 beyond the mutation)
were used in conjunction with internal sense and matching antisense
primers that contained the desired mutation. Three PCR reactions
were run, the ¢rst two providing the 5P and 3P ends of the mutated
fragment, and the third consecutive reaction joining the separate frag-
ments. The ¢nal PCR product was cut with BamHI and BstEII
(unique sites, one in the multiple cloning site of pcDNA3 and the
other in HA-CB2, beyond the area of the mutation), the mutated
fragment cloned into HA-CB2 and the DNA sequences of the various
HA-CB2 mutants con¢rmed.
2.5. Transient cell transfection
24 h before transfection, a con£uent 10 cm plate of COS-7 cells in
Dulbecco’s modi¢ed Eagle’s medium (DMEM), supplemented with
5% fetal calf serum, 100 U/ml penicillin and 100 Wg/ml streptomycin
in a humidi¢ed atmosphere consisting of 5% CO2 and 95% air at
37‡C, was trypsinized and split into ¢ve 10 cm plates. The cells
were transfected, using the DEAE-dextran chloroquine method [28],
with wild-type (wt) HA-CB2 cDNA (2 Wg/plate) or mutant cDNAs
(4 Wg/plate), and where indicated, with AC-V cDNA (1.5 Wg/plate).
pXMD1-gal cDNA was used for mock DNA transfection. For bind-
ing studies, 72 h after transfection, the COS cells were washed twice
with phosphate-bu¡ered saline (PBS), scraped, centrifuged at 3000
rpm for 10 min and the cell pellets stored at 370‡C. For AC assay,
48 h after transfection, the COS cells were trypsinized and re-cultured
in 24-well plates, and after an additional 24 h, the cells were assayed
for AC activity as described below. Transfection e⁄ciency was nor-
mally in the range of 40^80%, as determined by staining the cells for
the activity of transfected L-galactosidase [29].
2.6. AC activity
The assay was performed in triplicate as described previously [7,8].
In brief, cells cultured in 24-well plates were incubated for 2 h with
0.25 ml/well fresh growth medium containing 5 WCi/ml [2-3H]adenine.
This medium was replaced with DMEM containing 20 mM HEPES
(pH 7.4), and the phosphodiesterase inhibitors RO-20-1724 (0.5 mM)
and IBMX (0.5 mM). Cannabinoids diluted in 10 mg/ml FAF^BSA
were then added. AC activity was stimulated in the presence or ab-
sence of cannabinoids by the addition of 2 WM FS. After 10 min at
37‡C, the medium was removed and the reaction terminated by add-
ing to the cell layer 1 ml of 2.5% perchloric acid containing 0.1 mM
unlabeled cAMP. Aliquots of 0.9 ml of the acidic extract were neu-
tralized with 100 Wl of 3.8 M KOH and 0.16 M K2CO3 and applied to
a two-step column separation procedure [30]. The [3H]cAMP was
eluted into scintillation vials and counted. Background levels
(cAMP accumulation in the absence of stimulator) were subtracted
from all values.
2.7. Binding of [3H]HU-243
This assay was performed as described previously [8,31]. Frozen
pellets of transfected cells were homogenized in 2 ml/plate of binding
bu¡er and 100 Wl aliquots of crude cell homogenates containing 20^30
Wg protein (as determined by the Bradford method) were mixed with
300 pM of [3H]HU-243, in 1.5 ml Eppendorf tubes in a ¢nal volume
of 1 ml of 50 mM Tris^HCl, 5 mM MgCl2, 10 mM CaCl2, 2.5 mM
EDTA, pH 7.4, and 2 mg/ml FAF^BSA. The binding mixtures were
incubated at 30‡C for 1.5 h with gentle shaking and centrifuged at
14 000 rpm for 10 min. The bottoms of the 1.5 ml tubes were then cut
and counted for radioactivity. Non-speci¢c binding determined in the
presence of 1 WM HU-210 was subtracted from all values. To study
the binding a⁄nities of the cannabinoid agonists HU-210 and
WIN55,212-2, the indicated concentrations of these materials were
added to the binding mixtures together with the [3H]HU-243. The
Ki values for HU-210 and WIN55,212-2 were determined by the for-
mula Ki = IC50/1+([[3H]HU-243]/Kd) [31].
2.8. Sodium dodecyl sulfate^polyacrylamide gel electrophoresis and
Western immunoblotting
COS-7 cells transfected with the various HA-tagged CB2 cDNAs in
10 cm culture plates were harvested with cold PBS and spun down at
3000 rpm (at 4‡C for 10 min), and the cell pellets were mixed with
100 Wl/plate of Laemmli sample bu¡er, sonicated and frozen at
320‡C. Samples of 20 Wl were incubated for 5 min at 100‡C with
dithiothreitol (0.1 M ¢nal) prior to loading onto 1.5 mm thick 10%
polyacrylamide gel. Following electrophoresis, proteins were blotted
onto a nitrocellulose membrane and the blot blocked in PBS contain-
ing 5% fat-free milk and 0.5% Tween-20, followed by 1.5 h incubation
with anti-HA monoclonal antibody (HA.11, Boehringer Mannheim)
diluted 1:1000 in 5% fat-free milk and 0.5% Tween-20. Blots were
washed three times with PBS containing 0.3% Tween-20 and incu-
bated for 1 h with horseradish peroxidase-coupled rat anti-mouse
antibodies (Jackson Immunoresearch Laboratories) diluted 1:20 000
in 5% fat-free milk plus 0.5% Tween-20. The blot was extensively
washed and peroxidase activity was observed by the enhanced chem-
iluminescence technique (Amersham).
2.9. Data analysis
Data presented in the text and ¢gures are mean values þ S.E.M.
Statistical analysis of the data was done using the Student’s t-test.
Dose^response curves were plotted using the Sigma Plot 4.11 pro-
gram.
3. Results and discussion
There is evidence that the E/DRY sequence located at the
junction of TM3 and ICL2 of many GPCRs has a role in
various receptor functions, including receptor expression, con-
stitutive receptor activation, G protein coupling, receptor se-
questration and receptor internalization [11,19,20,22,23,32].
However, the role of this motif in the signal transduction of
the CB2 receptor has not yet been examined. We have there-
fore mutated the CB2 receptor (tagged with a HA epitope at
its N-terminus) at this site, replacing either individual amino
acids or all three of them with alanines, and examined the
cannabinoid binding activity and the signal transduction ca-
pacity of the mutants versus HA-CB2 (wt). HA-tagging of the
CB2 receptor did not a¡ect agonist binding, nor did it a¡ect
the modulation of AC activity by cannabinoid agonists (data
not shown).
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3.1. Ligand binding to the CB2 D130A mutant
Fig. 2A shows that compared to HA-CB2 (wt), the
DRY130^132AAA mutant retained only 15% of the binding
of the high a⁄nity cannabinoid agonist [3H]HU-243, and the
D130A mutant retained about 20%. On the other hand, the
R131A and Y132A mutants retained almost normal binding
activity of 80% and 70% speci¢c binding, respectively. This
implies that in CB2, the D130 residue seems to be involved in
the binding activity of the receptor, while R131 and Y132
would appear to be less important for this function. Even
though both DRY130^132AAA and D130A showed only lit-
tle cannabinoid agonist binding, we tested their signaling ca-
pacity and found that their activation by either HU-210 or
WIN55,212-2 did not lead to any signi¢cant AC inhibition
(data not shown). Thus, these mutants also appear to be de-
fective in their downstream signaling.
Fig. 2B is a control experiment demonstrating by Western
blot analysis that all the mutants used in this study are e⁄-
ciently expressed, and thus the reduction in binding to the
D130A mutant is not due to reduced expression. The molec-
ular weight observed for the major immunoreactive band was
41 kDa, which is consistent with the amino acid composition
of the HA-tagged receptor and with the molecular weight
obtained for the expressed human CB2 receptor protein [33].
This loss of binding by the D130A mutant, but not by the
R131A mutant, in CB2 is in agreement with the results ob-
tained by others for the m1-muscarinic receptor [17,21]. How-
ever, it should be noted that mutating the conserved D residue
in the E/DRY motif led to di¡erent results with di¡erent
receptors or receptor functions. A reduction in G protein
coupling with retention of high a⁄nity ligand binding was
observed with L- and K2-adrenergic receptors [34,35]. On the
other hand, mutation of D122 in the m1-muscarinic receptor
led to a decrease in the level of antagonist binding to the
receptor (depending on the amino acid replaced), but it was
claimed that the D122 residue does not directly participate in
the signaling [17]. Moreover, mutation of the D residue was
shown to promote constitutive receptor activation in rhodop-
sin [36] and in the K1B-adrenergic receptor [19,20], but not in
the m1-muscarinic receptor [17].
3.2. Ligand binding and signaling by the CB2 R131A mutant
Fig. 3A,B shows the competitive binding curves for the
cannabinoid agonists, HU-210 and WIN55,212-2, in COS
cells transfected with cDNAs of either HA-CB2 (wt) or the
R131A mutant. The data show that HU-210 binds with a Ki
of 145 þ 51 pM and 234 þ 52 pM for HA-CB2 (wt) and the
R131A mutant, respectively. WIN55,212-2 binds with a Ki of
1.0 þ 0.2 nM and 2.5 þ 0.3 nM for HA-CB2 (wt) and the
R131A mutant, respectively. Altogether, the R131A mutant
binds well both HU-210 and WIN55,212-2, with a⁄nities sim-
ilar to those of wt receptor. It should be noted that the Ki
values of HU-210 and WIN55,212-2 binding to HA-CB2 (wt)
as found here are in agreement with previous data obtained
by us and others for the binding to the CB2 receptor:
220 þ 180 pM [37], 147 þ 7 pM [38] and 170 þ 10 pM [31] for
HU-210, and 280 þ 160 pM for WIN55,212-2 [37].
This R residue was found to be absolutely conserved within
all of the members of the GPCR family [11,13] and its sub-
stitution in various GPCRs, such as the m1-muscarinic and
K1B-adrenergic receptors, severely reduced the agonist-induced
activation of phosphoinositide hydrolysis [19,21]. Oliveira et
al. [11] suggested that this R residue serves as an Arg-switch,
leading to activation of GPCRs (due to the shift of the
Fig. 2. Binding of [3H]HU-243 and expression of HA-CB2 (wt) and
mutants. COS cells were transfected with the cDNAs of HA-CB2
(wt) and the indicated mutants. (A) Binding of [3H]HU-243 to
equivalent aliquots of cell homogenates. Binding to HA-CB2 (wt) is
presented as 100%. The data represent the means þ S.E.M. of two
experiments. (B) Western blot analysis showing the expression of
the various mutants. Control represents mock-transfected cells.
Fig. 3. E¡ect of the R131A mutation on cannabinoid binding and
AC inhibition. (A,B) COS cells transfected with the cDNA of HA-
CB2 (wt) or of the R131A mutant were assayed for displacement of
[3H]HU-243 by increasing concentrations of HU-210 or WIN55,212-
2. (C,D) COS cells transfected as in (A,B), but also cotransfected
with AC-V, were assayed for the e¡ects of various concentrations of
HU-210 or WIN55,212-2 on FS-stimulated AC activity. Data repre-
sent the means þ S.E.M. of two experiments (A and B) or three ex-
periments (C and D).
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charged side chain upon agonist activation, thereby modulat-
ing G protein coupling). Indeed, a combination of mutagen-
esis and computational simulations on K1B-adrenergic and
GnRH receptors showed the importance of this Arg in signal-
ing [19,32].
We therefore analyzed the signaling of the R131A HA-CB2
mutant in comparison with HA-CB2 (wt). Fig. 3C,D shows
that G protein signaling by the R131A mutant is only weakly
a¡ected, as the EC50 values for the inhibition of transfected
AC-V by WIN55,212-2 and by HU-210 were shifted to the
right by less than 2-fold, in comparison to wt receptor. The
EC50 values for WIN55,212-2 were 1.34 þ 0.27 vs. 0.73 þ 0.2
nM, respectively, and for HU-210, 1.26 þ 0.03 vs. 0.78 þ 0.18
nM, respectively. The maximal levels of inhibition of AC-V by
HU-210 and WIN55,212-2 with the R131A mutant were
somewhat reduced compared with HA-CB2 (wt): 30% vs.
55% and 50% vs. 60%, respectively. Interestingly, AC signal-
ing by HU-210 was more a¡ected than by WIN55,212-2 in the
R131A mutant. This di¡erence between HU-210 and
WIN55,212-2 is not completely clear but could possibly be
explained by the ¢nding that the binding site for classical
cannabinoids (e.g. HU-210) is distinct from that for the ami-
noalkylindoles (e.g. WIN55,212-2) for both CB1 and CB2 re-
ceptors [39,40]. Altogether, mutating R131 in CB2 only
slightly a¡ected signaling. This result di¡ers from the obser-
vation made with the m1-muscarinic, GnRH and K1B-adrener-
gic receptors which, as described above, lost signaling capacity
upon mutation of this site [17,19,32].
3.3. Ligand binding and signaling by the CB2 Y132A mutant
Relatively little is known about the role of the Y residue of
the E/DRY motif in the GPCR superfamily. Replacing this
residue with non-aromatic amino acids led to a reduction in
the expression of the m1-muscarinic receptor binding sites,
with minimal e¡ects on the signaling capability of the ligand
binding receptors [17]. Fig. 4A,B shows the competitive bind-
ing curves for HU-210 and WIN55,212-2 in COS cells trans-
fected with HA-CB2 (wt) or the Y131A mutant. The data
show that agonist binding a⁄nity is not a¡ected by this mu-
tation. HU-210 binds with a Ki of 145 þ 51 pM and 160 þ 41
pM for HA-CB2 (wt) and the Y132A mutant, respectively.
WIN55,212-2 binds with a Ki of 1.0 þ 0.2 nM and 0.5 þ 0.2
nM for HA-CB2 (wt) and the Y132A mutant, respectively. We
next analyzed the signaling of the Y132A mutant. Fig. 4C,D
shows that the signaling by Y132A was markedly, but not
completely, reduced. The maximal inhibitions by HU-210
and by WIN55,212-2 for the Y132A mutant were reduced
as compared with HA-CB2 (wt) (26% vs. 55% and 28% vs.
60%, respectively).
Reports regarding the role of this Y residue in signal trans-
duction are controversial. Y3.51 was shown to have a role in
the signaling and internalization of the bradykinin B2 receptor
[22,23]. However, as described above, mutating this residue in
the m1-muscarinic receptor indicated that it is not critical for
e⁄cient signal transduction [17]. Moreover, converting the
unique DRS sequence in the GnRH receptor to the conserved
DRY sequence did not a¡ect receptor signaling [41]. Here, we
show that mutating this residue partially, but not completely,
interferes with receptor signaling.
In summary, the E/DRY motif at the junction of TM3 and
ICL2 is highly conserved in most members of the GPCR
superfamily. Whereas D130 in CB2 seems to be related to
receptor intramolecular contact a¡ecting ligand binding,
Y132 appears to have a possible role in receptor downstream
signaling.
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